Adial Pharmaceuticals Inc (ADIL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adial Pharmaceuticals Inc   (NASDAQ: ADIL)


Adial Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adial Pharmaceuticals Inc's ROI in the second quarter of 2026?
Adial Pharmaceuticals Inc recorded a cumulative net loss of $-58 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -617.09%.

Within the Healthcare sector 227 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 4074 to 4080.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 112.05 % 16.72 % -14.01 % -20.01 % 5.04 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 24 4 5 5 6
Return On Investment (TTM) -617.09 % -162.83 % -182.35 % -197.71 % -191.29 %
ADIL's Overall Ranking # 4080 # 4074 # 3681 # 3912 # 3404
Seq. Investment Change TTM 96.27 % 9.09 % 7.42 % -7.8 % 8.03 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -58 -8 -8 -8 -8

ADIL Company Profile >> Back to ADIL Roi Comparisons >> See Annual ADIL Return On Investment



Return On Investment ADIL's Ranking
Within: No.
Industry # 94
Sector # 228
Overall # 4080

Return On Investment Statistics
High Average Low
39.47 %
-191.32 %
-617.09 %
(Sep 30 2019)   (Jun 30 2026)



  News about Adial Pharmaceuticals Inc Return on Investment ROI

Adial Pharmaceuticals on the Horizon of Change: Financial Challenges and Breakthroughs in Alcohol Use Disorder Treatment,

November 13, 2024

Overview of Financial PerformanceAdial Pharmaceuticals, Inc. (NASDAQ: ADIL), a pioneering biopharmaceutical firm based in Glen Allen, Virginia, recently published its financial results for the third quarter of 2024 and provided a comprehensive business update. The company operates in the healthcare sector, focusing on the development of therapies aimed at treating and preventing addiction and related disorders.During a one-year frame leading up to the second quarter of 2024, Adial recorded a cumulative net loss of $9 million. This financial strain has translated into a concerning negative return on investment (ROI) of -230.01%. Notably, within the healthcare industry, there were 503 other companies that demonstrated a higher ROI during the same period. However, it s worth mentioning that Adial has made strides in its overall ROI ranking, advancing from 3642 in Q1 2024 to 3144 by the end of Q2 2024. This upward trend indicates a potential for improved financial stability or performance in the future.

“Adial Pharmaceuticals Pioneers New Pathways for Alcohol Use Disorder Treatment in Light of Evolving Recovery Definitions,

October 15, 2024

Advancements in Alcohol Use Disorder Treatment: Adial Pharmaceuticals and the Evolving Landscape of Recovery DefinedIn a pivotal moment for the treatment of Alcohol Use Disorder (AUD), Adial Pharmaceuticals is at the forefront of innovation, aligning its research efforts with the National Institute on Alcohol Abuse and Alcoholism s (NIAAA) newly defined parameters for recovery. As the NIAAA shifts its focus to include non-abstinence solutions, Adial s investigational drug, AD04, stands as a beacon of hope for millions struggling with alcohol dependence. The company s recent developments not only validate the market potential for its pioneering therapy but also highlight a significant evolution in the understanding of recovery from alcohol addiction.In September 2023, Adial Pharmaceuticals achieved a notable milestone with the announcement of a database lock in its pharmacokinetics study of AD04. This pivotal step signals the completion of data collection, positioning the company for the critical analysis phase where the implications of the study will start to crystallize. Anticipated topline results, expected to be disclosed in the fourth quarter of 2024, will provide vital information regarding AD04 s metabolization and efficacy, establishing a foundation for future regulatory submissions and drug approvals.





Financial Statements
Adial Pharmaceuticals Inc's II. Quarter Investments $ 24 Millions ADIL's Balance sheet
Adial Pharmaceuticals Inc's II. Quarter Income $ -52 Millions Quarterly ADIL's Income Statement
ADIL's Income by Division See ADIL's Income by Division


ADIL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 5 4 4 4 5
Y / Y Investment Growth 29.7 % -0.39 % 3.6 % -16.72 % 18.74 %
Net Income in Millions -8 -13 -5 -13 -19
Y / Y Net Income Growth - - - - -
Annual Return On Investment -151.18 % -324.41 % -125.45 % -322.98 % -410.36 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADIL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADIL's Competitors
Subscribers only: Roi for Adial Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ADIL's Customers

Other Ratios
ADIL's Roa ADIL's Inventory Turnover Ratio ADIL's Growth Rates ADIL's Dividend Statistics
ADIL's Profitability Ratios ADIL's Asset Turnover Ratio ADIL's Dividend Growth
ADIL's Roe ADIL's Valuation Ratios ADIL's Financial Strength Ratios ADIL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:34:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.